Literature DB >> 10049270

Antimicrobial activities of synthetic bismuth compounds against Clostridium difficile.

D E Mahony1, S Lim-Morrison, L Bryden, G Faulkner, P S Hoffman, L Agocs, G G Briand, N Burford, H Maguire.   

Abstract

Clostridium difficile is a major nosocomial pathogen responsible for pseudomembranous colitis and many cases of antibiotic-associated diarrhea. Because of potential relapse of disease with current antimicrobial therapy protocols, there is a need for additional and/or alternative antimicrobial agents for the treatment of disease caused by C. difficile. We have synthesized a systematic series of 14 structurally simple bismuth compounds and assessed their biological activities against C. difficile and four other gastrointestinal species, including Helicobacter pylori. Here, we report on the activities of six compounds that exhibit antibacterial activities against C. difficile, and some of the compounds have MICs of less than 1 microgram/ml. Also tested, for comparison, were the activities of bismuth subcitrate and ranitidine bismuth citrate obtained from commercial sources. C. difficile and H. pylori were more sensitive both to the synthetic bismuth compounds and to the commercial products than were Escherichia coli, Pseudomonas aeruginosa, and Proteus mirabilis, and the last three species were markedly resistant to the commercial bismuth salts. Testing with human foreskin fibroblast cells revealed that some of the synthetic compounds were more cytotoxic than others. Killing curves for C. difficile treated with the more active compounds revealed rapid death, and electron microscopy showed that the bismuth of these compounds was rapidly incorporated by C. difficile. Energy dispersive spectroscopy X-ray microanalysis of C. difficile cells containing electron-dense material confirmed the presence of internalized bismuth. Internalized bismuth was not observed in C. difficile treated with synthetic bismuth compounds that lacked antimicrobial activity, which suggests that the uptake of the metal is required for killing activity. The nature of the carrier would seem to determine whether bismuth is transported into susceptible bacteria like C. difficile.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049270      PMCID: PMC89163     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Enhancement of bismuth antibacterial activity with lipophilic thiol chelators.

Authors:  P Domenico; R J Salo; S G Novick; P E Schoch; K Van Horn; B A Cunha
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  The Structurally Flexible Bicyclic Bis(2-hydroxyethanethiolato)bismuth(III) Complex: A Model for Asymmetric Monoanionic Chelation of Bismuth(III).

Authors:  Lisa Agocs; Glen G. Briand; Neil Burford; T. Stanley Cameron; Witold Kwiatkowski; Katherine N. Robertson
Journal:  Inorg Chem       Date:  1997-06-18       Impact factor: 5.165

Review 3.  The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology.

Authors:  B J Marshall
Journal:  Am J Gastroenterol       Date:  1991-01       Impact factor: 10.864

4.  Use of bismuth subsalicylate for the prevention of travelers' diarrhea.

Authors:  H L DuPont; C D Ericsson; P C Johnson; F J de la Cabada
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

Review 5.  Bismuth subsalicylate: history, chemistry, and safety.

Authors:  D W Bierer
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

6.  Use of bismuth subsalicylate in acute diarrhea in children.

Authors:  H E Soriano-Brücher; P Avendaño; M O'Ryan; H A Soriano
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

7.  Deposition of bismuth by Yersinia enterocolitica.

Authors:  O W Nadeau; D W Gump; G M Hendricks; D H Meyer
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 8.  Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.

Authors:  S J Veldhuyzen van Zanten; P M Sherman
Journal:  CMAJ       Date:  1994-01-15       Impact factor: 8.262

9.  Binding and killing of bacteria by bismuth subsalicylate.

Authors:  T E Sox; C A Olson
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

10.  Effect of bismuth subsalicylate on chronic diarrhea in childhood: a preliminary report.

Authors:  J D Gryboski; S Kocoshis
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb
View more
  10 in total

1.  Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile.

Authors:  D E Mahony; A Woods; M D Eelman; N Burford; S J O Veldhuyzen van Zanten
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  Topical antimicrobials for burn infections - an update.

Authors:  Mert Sevgi; Ani Toklu; Daniela Vecchio; Michael R Hamblin
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2013-12

3.  Activities of bismuth thiols against staphylococci and staphylococcal biofilms.

Authors:  P Domenico; L Baldassarri; P E Schoch; K Kaehler; M Sasatsu; B A Cunha
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.

Authors:  Paul S Hoffman; Gary Sisson; Matthew A Croxen; Kevin Welch; W Dean Harman; Nunilo Cremades; Michael G Morash
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

5.  Antibacterial properties of some cyclic organobismuth(III) compounds.

Authors:  Toshiaki Kotani; Daisuke Nagai; Kensuke Asahi; Hitomi Suzuki; Fumiaki Yamao; Nobumasa Kataoka; Tatsuo Yagura
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Metabolism of bismuth subsalicylate and intracellular accumulation of bismuth by Fusarium sp. strain BI.

Authors:  Anthony G Dodge; Lawrence P Wackett
Journal:  Appl Environ Microbiol       Date:  2005-02       Impact factor: 4.792

7.  Bismuth nanoparticles obtained by a facile synthesis method exhibit antimicrobial activity against Staphylococcus aureus and Candida albicans.

Authors:  Roberto Vazquez-Munoz; M Josefina Arellano-Jimenez; Jose L Lopez-Ribot
Journal:  BMC Biomed Eng       Date:  2020-10-14

8.  Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Authors:  Cirle A Warren; Edward van Opstal; T Eric Ballard; Andrew Kennedy; Xia Wang; Mary Riggins; Igor Olekhnovich; Michelle Warthan; Glynis L Kolling; Richard L Guerrant; Timothy L Macdonald; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

9.  Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens.

Authors:  Adam M Pitz; Geun Woo Park; David Lee; Ying L Boissy; Jan Vinjé
Journal:  Gut Microbes       Date:  2015

10.  Fast, facile synthesis method for BAL-mediated PVP-bismuth nanoparticles.

Authors:  Roberto Vazquez-Munoz; M Josefina Arellano-Jimenez; Jose L Lopez-Ribot
Journal:  MethodsX       Date:  2020-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.